Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

Bookmark and Share
Published: 19 Dec 2019
Views: 124
Rating:
Save
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Dr Sarah Nikiforow speaks to ecancer at the 2019 ASH meeting in Orlando about a study looking at long-term outcomes of subjects with EBV (Epstein-Barr virus) driven PTLD (post-transplant lymphoproliferative disorder) following solid organ or allogeneic HCT treated with tabelecleucel.

She explains that the safety was reported from 61 patients enrolled in the trial and was proved to be incredibly safe during the infusion process and only 9% of patients had grade 3 or higher treatment related SAEs.

Dr Nikiforow reports that in the solid organ and allogeneic HCT groups the overall response rates were 80% and 50% respectively.